Cystamine modulation of galactosamine-induced hepatotoxicity

John R. MacDonald, A Jay Gandolfi, I. Glenn Sipes

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The ability of cystamine treatment to protect against galactosamine-induced hepatic necrosis was investigated. Reduced hepatotoxicity was observed following galactosamine hydrochloride (400 mg/kg, ip) in male Sprague-Dawley rats that received cystamine dihydrochloride (300 mg/kg, po) 30 min prior to or 2, 4, 6, 8, or 12 hr after galactosamine, In contrast, uridine treatment only protected against galactosamine-induced liver damage if administered within 2 hr of galactosamine. Protection by cystamine was found to extend over 3 days during which time the lesion was resolving. The degree of protection was dose related when administered 12 hr after galactosamine. Cystamine did not prevent or alter the increase in hepatic Ca2+ seen following galactosamine administration. The results indicate that the protective effects of cystamine on galactosamine-induced hepatotoxicity are unrelated to prevention of the early biochemical events that initiate the injury. Furthermore, prevention of Ca2+ accumulation in damaged hepatocytes is not the mechanism of protection and hence is not necessarily an irreversible cytotoxic event.

Original languageEnglish (US)
Pages (from-to)551-558
Number of pages8
JournalToxicology and Applied Pharmacology
Volume73
Issue number3
DOIs
StatePublished - 1984

Fingerprint

Cystamine
Galactosamine
Modulation
Liver
Uridine
Sprague Dawley Rats
Rats
Hepatocytes
Necrosis

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Cystamine modulation of galactosamine-induced hepatotoxicity. / MacDonald, John R.; Gandolfi, A Jay; Sipes, I. Glenn.

In: Toxicology and Applied Pharmacology, Vol. 73, No. 3, 1984, p. 551-558.

Research output: Contribution to journalArticle

MacDonald, John R. ; Gandolfi, A Jay ; Sipes, I. Glenn. / Cystamine modulation of galactosamine-induced hepatotoxicity. In: Toxicology and Applied Pharmacology. 1984 ; Vol. 73, No. 3. pp. 551-558.
@article{9b492db602b349d7bc24bcc7263140ee,
title = "Cystamine modulation of galactosamine-induced hepatotoxicity",
abstract = "The ability of cystamine treatment to protect against galactosamine-induced hepatic necrosis was investigated. Reduced hepatotoxicity was observed following galactosamine hydrochloride (400 mg/kg, ip) in male Sprague-Dawley rats that received cystamine dihydrochloride (300 mg/kg, po) 30 min prior to or 2, 4, 6, 8, or 12 hr after galactosamine, In contrast, uridine treatment only protected against galactosamine-induced liver damage if administered within 2 hr of galactosamine. Protection by cystamine was found to extend over 3 days during which time the lesion was resolving. The degree of protection was dose related when administered 12 hr after galactosamine. Cystamine did not prevent or alter the increase in hepatic Ca2+ seen following galactosamine administration. The results indicate that the protective effects of cystamine on galactosamine-induced hepatotoxicity are unrelated to prevention of the early biochemical events that initiate the injury. Furthermore, prevention of Ca2+ accumulation in damaged hepatocytes is not the mechanism of protection and hence is not necessarily an irreversible cytotoxic event.",
author = "MacDonald, {John R.} and Gandolfi, {A Jay} and Sipes, {I. Glenn}",
year = "1984",
doi = "10.1016/0041-008X(84)90107-8",
language = "English (US)",
volume = "73",
pages = "551--558",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Cystamine modulation of galactosamine-induced hepatotoxicity

AU - MacDonald, John R.

AU - Gandolfi, A Jay

AU - Sipes, I. Glenn

PY - 1984

Y1 - 1984

N2 - The ability of cystamine treatment to protect against galactosamine-induced hepatic necrosis was investigated. Reduced hepatotoxicity was observed following galactosamine hydrochloride (400 mg/kg, ip) in male Sprague-Dawley rats that received cystamine dihydrochloride (300 mg/kg, po) 30 min prior to or 2, 4, 6, 8, or 12 hr after galactosamine, In contrast, uridine treatment only protected against galactosamine-induced liver damage if administered within 2 hr of galactosamine. Protection by cystamine was found to extend over 3 days during which time the lesion was resolving. The degree of protection was dose related when administered 12 hr after galactosamine. Cystamine did not prevent or alter the increase in hepatic Ca2+ seen following galactosamine administration. The results indicate that the protective effects of cystamine on galactosamine-induced hepatotoxicity are unrelated to prevention of the early biochemical events that initiate the injury. Furthermore, prevention of Ca2+ accumulation in damaged hepatocytes is not the mechanism of protection and hence is not necessarily an irreversible cytotoxic event.

AB - The ability of cystamine treatment to protect against galactosamine-induced hepatic necrosis was investigated. Reduced hepatotoxicity was observed following galactosamine hydrochloride (400 mg/kg, ip) in male Sprague-Dawley rats that received cystamine dihydrochloride (300 mg/kg, po) 30 min prior to or 2, 4, 6, 8, or 12 hr after galactosamine, In contrast, uridine treatment only protected against galactosamine-induced liver damage if administered within 2 hr of galactosamine. Protection by cystamine was found to extend over 3 days during which time the lesion was resolving. The degree of protection was dose related when administered 12 hr after galactosamine. Cystamine did not prevent or alter the increase in hepatic Ca2+ seen following galactosamine administration. The results indicate that the protective effects of cystamine on galactosamine-induced hepatotoxicity are unrelated to prevention of the early biochemical events that initiate the injury. Furthermore, prevention of Ca2+ accumulation in damaged hepatocytes is not the mechanism of protection and hence is not necessarily an irreversible cytotoxic event.

UR - http://www.scopus.com/inward/record.url?scp=0021239756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021239756&partnerID=8YFLogxK

U2 - 10.1016/0041-008X(84)90107-8

DO - 10.1016/0041-008X(84)90107-8

M3 - Article

C2 - 6719469

AN - SCOPUS:0021239756

VL - 73

SP - 551

EP - 558

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 3

ER -